These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1184 related items for PubMed ID: 17366054

  • 1. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K.
    Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
    [Abstract] [Full Text] [Related]

  • 2. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 3. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B.
    J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
    [Abstract] [Full Text] [Related]

  • 4. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM, Gharib MI, Turner AJ, Guiver M, Carr T, Will AM, Wynn RF.
    Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
    [Abstract] [Full Text] [Related]

  • 5. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C, Giacchino F, Bergallo M, Bonello F, Bollero C, Segoloni GP, Cavallo R.
    G Ital Nefrol; 2003 Aug; 20(2):170-5. PubMed ID: 12746803
    [Abstract] [Full Text] [Related]

  • 6. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 7. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA.
    Clin Transplant; 2006 Jan; 20(3):389-93. PubMed ID: 16824159
    [Abstract] [Full Text] [Related]

  • 8. [EBV quantification in children after allogeneic hematopoietic stem cell transplantation].
    Hubácek P, Cinek O, Kulich M, Zajac M, Keslová P, Formánková R, Starý J, Sedlácek P.
    Cas Lek Cesk; 2006 Jan; 145(4):301-6. PubMed ID: 16639931
    [Abstract] [Full Text] [Related]

  • 9. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
    Clave E, Agbalika F, Bajzik V, Peffault de Latour R, Trillard M, Rabian C, Scieux C, Devergie A, Socié G, Ribaud P, Adès L, Ferry C, Gluckman E, Charron D, Esperou H, Toubert A, Moins-Teisserenc H.
    Transplantation; 2004 Jan 15; 77(1):76-84. PubMed ID: 14724439
    [Abstract] [Full Text] [Related]

  • 10. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S, Behnke-Hall K, Gruhn B, Bauer J, Horn M, Beck J, Reiter A, Wagner HJ.
    J Clin Virol; 2012 Mar 15; 53(3):186-94. PubMed ID: 22182950
    [Abstract] [Full Text] [Related]

  • 11. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C, Cavallo R, Bergallo M, Giacchino F, Bollero C, Negro Ponzi A, Cavallo G.
    New Microbiol; 2003 Apr 15; 26(2):141-9. PubMed ID: 12737195
    [Abstract] [Full Text] [Related]

  • 12. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.
    Biol Blood Marrow Transplant; 2011 Jun 15; 17(6):901-7. PubMed ID: 20950702
    [Abstract] [Full Text] [Related]

  • 13. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
    Ahmad I, Cau NV, Kwan J, Maaroufi Y, Meuleman N, Aoun M, Lewalle P, Martiat P, Crokaert F, Bron D.
    Transplantation; 2009 Apr 27; 87(8):1240-5. PubMed ID: 19384173
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients.
    Toyoda M, Moudgil A, Warady BA, Puliyanda DP, Jordan SC.
    Pediatr Transplant; 2008 Nov 27; 12(7):778-84. PubMed ID: 18331541
    [Abstract] [Full Text] [Related]

  • 15. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep 27; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 16. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
    Garceau P, Couture C, Cantin B, Bernier V, Sénéchal M.
    J Heart Lung Transplant; 2008 Aug 27; 27(8):928-31. PubMed ID: 18656811
    [Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease.
    Carpentier L, Tapiero B, Alvarez F, Viau C, Alfieri C.
    J Infect Dis; 2003 Dec 15; 188(12):1853-64. PubMed ID: 14673764
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
    Doesch AO, Konstandin M, Celik S, Kristen A, Frankenstein L, Sack FU, Schnabel P, Schnitzler P, Katus HA, Dengler TJ.
    Transpl Int; 2008 Oct 15; 21(10):963-71. PubMed ID: 18564989
    [Abstract] [Full Text] [Related]

  • 19. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation.
    Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E, Tridello G, Varotto S, Alaggio R, Zanesco L, Palù G, Messina C.
    Br J Haematol; 2005 Jan 15; 128(2):224-33. PubMed ID: 15638858
    [Abstract] [Full Text] [Related]

  • 20. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.
    Clin Transplant; 2013 Jan 15; 27(4):E491-7. PubMed ID: 23781897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.